A molecule squeezed from a desert toad is now the subject of a two-company pharmaceutical race, and Wall Street is already pricing in an approval that does not exist yet. The business story is who owns a drug that grows in nature.
Biotech companies are racing to turn 5-MeO-DMT, an extremely potent psychedelic found in the venom of the Sonoran Desert toad, into an approved treatment for depression, anxiety and PTSD. Two firms lead the field with rival delivery methods, both eyeing Phase 3 trials in 2026. One of them carries a $1.65 billion valuation on zero product revenue. The prize is a slice of a market forecast to nearly double this decade.
The Wall Street Journal put a spotlight on the compound on July 14, framing it as the “world’s most powerful psychedelic” and asking why the industry is betting big on a toad poison. The more useful question for anyone watching business models is a different one: how do you build a durable, patent-protected franchise around a substance that occurs naturally and has been used, unregulated, for years?
What Happened
The Journal published a video investigation into the commercial race behind 5-MeO-DMT, also known as mebufotenin, showing how the psychedelic is already being administered at unregulated clinics while pharmaceutical companies chase a regulated, FDA-approved version. The framing was blunt: this could become a billion-dollar blockbuster.
That race now has two clear frontrunners. GH Research, a Dublin-based company listed on the Nasdaq, is developing an inhaled formulation called GH001. Its rival, the merged entity atai Beckley, is developing an intranasal spray called BPL-003. Both target treatment-resistant depression, the roughly one-third of depression cases that do not respond to standard antidepressants, and both reported positive mid-stage results within months of each other.
The commercial logic is speed. Both drugs are designed to work fast and from a single dose, a sharp contrast to daily antidepressants that can take weeks to act. GH Research’s Phase 2b data showed a 15.5-point reduction on a standard depression scale versus placebo by day 8, with 57.5% of patients in remission. atai Beckley’s nasal spray earned a Breakthrough Therapy designation from the FDA in October 2025, a status meant to speed development.
The Backstory
5-MeO-DMT is not new. It is one of the most powerful naturally occurring psychedelics known, historically harvested from the Bufo alvarius toad and used in ceremonial and underground settings well before any biotech got involved. That history is exactly what makes the commercialization play tricky, and interesting.
For GH Research, the road has been bumpy. The FDA placed a clinical hold on its lead program in 2023, demanding more inhalation toxicology work and device specifications. It took until January 2026 for the agency to lift that hold and clear U.S. enrollment. Around the same time, the regulatory weather shifted in the sector’s favor. A White House executive order signed on April 18, 2026, directed the government to accelerate research and access for psychedelic treatments targeting serious mental illness, and GH Research publicly welcomed it.
The competitive picture also consolidated. atai Life Sciences and Beckley Psytech, which had been developing BPL-003 separately, completed a planned combination once the Phase 2b data delivered, forming atai Beckley and turning what could have been three players into a cleaner two-horse race for the same molecule.
The Plan
Both companies are running the classic single-asset biotech playbook: prove the drug in trials, secure a regulatory moat, and either commercialize or get acquired by a larger drugmaker. GH Research plans to start its pivotal Phase 3 program in the second half of 2026 and is also developing an intravenous version, GH002, as a second shot on goal.
The financial firepower is real. GH Research reported $267.3 million in cash and securities as of March 2026, then raised roughly $111 million more in an April share offering, giving it a runway measured in years against a quarterly net loss near $19 million. For a company with 73 employees and one core molecule, that is a well-funded bet.
atai Beckley’s plan leans on its Breakthrough designation and a delivery method some analysts view as more practical than an inhalation device that, in trials, relied on a repurposed medical vaporizer. The nasal spray uses a device format already familiar from approved products, which matters for eventual scale-up and physician adoption.
The Business Model Angle
Here is where the toad story gets sharp. The entire pharmaceutical business model rests on patent-protected exclusivity. A company like Pfizer or Merck spends years and often more than a billion dollars developing a compound, then relies on patents to sell it without competition long enough to earn that investment back. The blockbuster model only works if you can keep everyone else out.
5-MeO-DMT breaks the usual setup. You cannot patent a molecule that occurs in nature. So the race is not really about who owns the compound. It is about who owns the delivery system, the formulation, the dosing regimen and the device wrapped around it. GH Research’s moat is a proprietary inhalation approach. atai Beckley’s moat is a specific benzoate salt in a nasal spray. The value sits in the packaging, not the drug.
That creates two consequences worth noting. First, the two companies have filed heavily overlapping patents on similar ground, setting up a likely IP fight that Psychedelic Alpha memorably called a “Mebufotenin Melee.” Second, the market is already assigning enormous value to that thin moat. GH Research trades near $1.65 billion with no product on the market and no revenue, which means investors are paying today for the probability of an approval that has not happened. The underlying market supports the optimism: analysts peg the psychedelic drug market at roughly $4.6 billion in 2026, rising toward $8.75 billion by 2031, with treatment-resistant depression the single largest slice.
The Risk
The valuations assume the drugs clear Phase 3, and psychedelic trials carry a specific hazard: it is nearly impossible to blind them. Patients generally know whether they received a powerful psychedelic or a placebo, which can inflate apparent efficacy. The FDA has already flagged this exact problem in other psychedelic programs. A Phase 3 stumble would reprice these companies fast.
There is also the shadow market. 5-MeO-DMT is available right now at unregulated clinics, which means an approved version has to justify a premium over something people can already access. And the naturally occurring nature of the compound cuts both ways: the same feature that blocks a molecule patent also invites future competition and formulation workarounds once the category is validated. A thin moat protects thin.
Quick Questions
What is 5-MeO-DMT? An extremely potent psychedelic, also called mebufotenin, found in the venom of the Sonoran Desert toad and in some plants. It is being developed as a fast-acting treatment for depression.
Which companies are racing to commercialize it? GH Research, with an inhaled formulation called GH001, and atai Beckley, with an intranasal spray called BPL-003. Both target treatment-resistant depression.
Why can’t a company just patent the drug? Because 5-MeO-DMT occurs in nature. Companies instead patent the formulation, dosing regimen and delivery device, which is where the commercial value and the legal fights concentrate.
How big is the market? The broader psychedelic drug market is forecast at roughly $4.6 billion in 2026 and around $8.75 billion by 2031, with treatment-resistant depression the largest application.
The Business Model Analyst Take
The toad is a great headline, but it buries the actual lesson. This is a case study in what happens when a business model that depends on exclusivity collides with a product it cannot legally own. The pharmaceutical industry has spent a century perfecting the patent-moat playbook, and 5-MeO-DMT quietly dismantles the first assumption behind it.
What GH Research and atai Beckley are really selling is not a molecule. It is a wrapper: a device, a formulation, a dosing protocol and, above all, an FDA label that says “approved” in a market where the alternative is an unregulated clinic. That label is the moat. It is narrower than a composition-of-matter patent, which is why the IP overlap between the two companies is already heading toward a fight, and why a $1.65 billion valuation on zero revenue should be read as a bet on regulatory timing, not on a defensible product.
The instructive part for founders and operators has nothing to do with psychedelics. It is that value migrates to whatever layer you can actually defend. When you cannot own the core asset, you win by owning the packaging around it, the distribution, the trust, the regulatory position. That is true for a toad venom antidepressant, and it is true for a lot of businesses built on ingredients anyone can buy.
Based on reporting from The Wall Street Journal, with additional data from SEC filings, GH Research and atai Beckley disclosures, Psychedelic Alpha, and market research from Mordor Intelligence.
